Hypertensive disorders of pregnancy and cardiovascular disease risk: a Mendelian randomisation study

Lena Tschiderer1, Yvonne T van der Schouw2, Stephen Burgess3,4,5

  • 1Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria.

PubMed

Insights

Genetic predisposition to hypertensive disorders of pregnancy (HDPs) increases cardiovascular disease (CVD) risk. This genetic liability is linked to higher blood pressure and earlier hypertension diagnosis, suggesting a causal relationship with CVD.

Area of Science:

  • Cardiovascular Health
  • Genetics
  • Obstetrics & Gynecology

Background:

  • Hypertensive disorders of pregnancy (HDPs) are linked to adverse maternal cardiovascular disease (CVD) risk profiles.
  • Observational studies suggest a connection between HDPs and later-life CVD risk.

Purpose of the Study:

  • To investigate the association between genetic liability to HDPs (pre-eclampsia/eclampsia and gestational hypertension) and CVD risk factors.
  • To determine if genetic predisposition to HDPs is linked to the occurrence of CVD events like myocardial infarction or stroke.

Main Methods:

  • Utilized Mendelian randomization with individual participant data from the UK Biobank.
  • Analyzed genetic associations with HDPs from genome-wide association studies.
  • Included ever pregnant women in the primary analysis, with sensitivity analyses in nulligravidae and men.

Main Results:

  • Genetic liability to HDPs showed increased odds of CVD (ORs 1.20-1.24 per unit increase).
  • Associated with higher systolic/diastolic blood pressure and earlier hypertension diagnosis.
  • Sensitivity analyses in men and nulligravidae supported these findings.

Conclusions:

  • Genetic liability to HDPs is causally related to increased CVD risk.
  • Biological mechanisms underlying HDPs appear to contribute to CVD development.
  • Findings were consistent across ever pregnant women, nulligravidae, and men.
Abstract

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
31
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
453